Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 25Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 5Breast Neoplasms 5Pancreatic Neoplasms 4Carcinoma, Squamous Cell 4Stomach Neoplasms 3Esophageal Neoplasms 3Brain Neoplasms 3Prostatic Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2NSCLC 2Glioblastoma 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unilateral HER2 Positive Breast Cancer 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1Squamous Cell Cancers of the Head and Neck 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × PFS × Afatinib × Clear all
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡